SLXN (Silexion Therapeutics Corp) Net earnings per share growth this year

SLXN (Silexion Therapeutics Corp) - company brandmark

High dependence on third-party CROs/CMOs creates market volatility, causing the annual EPS growth metric to exhibit sharp fluctuations, with the indicator reaching the level of 47.90. Silexion Therapeutics Corp (SLXN) ensures stability through partnerships with biotech centers focused on combating KRAS mutations. The business is protected by strict FDA regulations and a patent monopoly on RNA interference, which create insurmountable barriers for competitors.

Earnings per share growth in current year: Silexion Therapeutics Corp. (SLXN) for 08/17/2024 - 11/18/2026

Financial and market metric breakdowns for Silexion Therapeutics Corp. (SLXN)

Summary company analysis:SLXN Silexion Therapeutics
Signature product of Silexion Therapeutics

Silexion Therapeutics Corp (SLXN) development of innovative RNA drugs targeting KRAS mutations makes the company dependent on the efficiency of investments in clinical trials. The eps_yy_co metric measures the annual dynamics of net income per share, reflecting the actual speed of capital scaling by comparing current and prior periods. The current EPS YoY change level is 47.90, allowing investors to assess the fundamental stability of the business and the risks of asset overvaluation.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences Inc INBX|I-Mab - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year herontx.com|NVCT: Earnings growth in current year|Net earnings per share change in current year Coherus CHRS|Net earnings per share growth this year CRBP|Earnings per share growth rate in current year Cardiff Oncology CRDF|Net earnings per share growth this year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Earnings per share increase in current year|Lixte Biotechnology - Net earnings per share growth this year|Net earnings per one share growth for the current year CTXR (Citius Pharma)|Cellectar - Earnings growth in current year|Earnings per share increase in current year BLRX (BioLineRx Corp)|CANF: Earnings growth in current year|Earnings per share growth rate in current year Aprea (APRE)|Earnings per share growth in current year kaziatherapeutics.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year